Business
New contract in progressive supranuclear palsy
New contract in progressive supranuclear palsy.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 2557D IXICO plc 30 January 2018 \n\n30 January 2018\n \nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nNew $2.7m contract in progressive supranuclear palsy with a global pharmaceutical company\n \n \nIXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed an additional new contract with an existing global pharmaceutical customer. The contract value is $2.7m, over a seven year term, to commence immediately.\n \nIXICO will provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy ('PSP'), a rare neurodegenerative disease.\n \nPSP is caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. This new contract is IXICO's third clinical trial project in PSP and follows contracts announced in October 2016 and March 2017 with values of $1.2m and $1.5m respectively. These contracts, together with two new Huntington's disease contracts announced in September 2017, demonstrate the depth and breadth of IXICO's capabilities and expert knowledge, as it continues to win novel neurodegenerative disease projects.\n \nAs part of the study, IXICO will use its TrialTracker™ digital platform and image analysis algorithms to collect and analyse MRI data from specialist imaging centres across Europe, North America and Australasia. This data will be used to evaluate the safety and efficacy of this novel treatment.\n \nGiulio Cerroni, CEO of IXICO, said: \"This additional, new contract in PSP from an existing customer indicates the value our customers see in IXICO's extensive neurological disease expertise combined with our proprietary digital technologies. Through our proven ability to collect and analyse clinical data in a standardized and regulatory-complaint format, we continue to build on our successful track record as a partner of choice to the biopharmaceutical industry\".\n \nFor further information please contact:\n \n\n\n\n\nIXICO plc \nGiulio Cerroni, Chief Executive Officer\nSusan Lowther, Chief Financial Officer\n\n\n \nTel: +44 20 3763 7499\n\n\n\n\n\n\n\n\n\n\n\n\nShore Capital (Nomad and Broker)\nEdward Mansfield /Anita Ghan...